Obesity increases asthma risk by 30-50% and worsens it across all inflammatory subtypes, prompting researchers to call for clinical trials of GLP-1 drugs specifically for asthma patients with obesity.
30-50% higher riskPeople with obesity have a 30-50% increased risk of developing asthma, and up to 70% of adult asthma patients are overweight or obese
What the researchers found
Obesity increases the risk of developing asthma by 30-50% and is one of the most common comorbidities in people with established asthma, with up to 70% of adult asthma patients being overweight or obese. The review challenges the simplistic view that obesity-related asthma is only a "Type-2-low" phenotype, showing instead that excess fat affects asthma across the entire inflammatory spectrum through multiple mechanisms including dysregulated adipokine signaling, systemic inflammation, metabolic dysfunction, and mechanical compression of the lungs.
Critically for the peptide field, the authors call for randomized, placebo-controlled trials of GLP-1 and dual GLP-1/GIP agonist therapies specifically in asthma patients with obesity. Weight reduction — whether through lifestyle changes, drugs, or bariatric surgery — improves asthma symptoms, lung function, and exacerbation risk regardless of the inflammatory subtype. Patients with obesity respond similarly to anti-T2 biologics for reducing exacerbations as lean patients, though symptom and lung function improvements are more variable.
Why it matters
With GLP-1 agonists driving unprecedented weight loss in clinical practice, this review makes the case that these peptide drugs could become important tools for managing asthma — not by targeting the lungs directly, but by reducing obesity-driven inflammation and mechanical burden. The explicit call for GLP-1/GIP agonist trials in asthma signals a major potential expansion of the peptide therapeutic landscape.
The numbers in context
650M+ adults with obesity globally · 30-50% higher asthma risk · Up to 70% of asthma patients overweight/obese · Mean BMI in asthma trials: 28-30 kg/m²
How the study worked
Narrative review published in the European Respiratory Journal synthesizing evidence on the epidemiology, pathophysiology, and treatment of obesity-associated asthma, with specific attention to the role of weight reduction therapies including GLP-1 agonists.
Who was studied
Not applicable (review covering adults with obesity and asthma)
What this study cannot tell us
As a narrative review, it reflects expert synthesis rather than systematic methodology. The call for GLP-1 trials in asthma is based on extrapolation from weight loss data rather than direct evidence. The heterogeneity of obesity-related asthma phenotypes means treatment effects may vary substantially between individuals.
How to read the evidence
Published in the European Respiratory Journal, a top-tier respiratory medicine publication. This is a comprehensive narrative review by experts in the field, synthesizing strong epidemiological and clinical evidence, though it does not present new experimental data.
When this study was published
Published in 2026 in the European Respiratory Journal. Highly current and reflects the latest thinking on obesity-asthma interactions and the potential role of GLP-1 therapies.
The bigger picture
GLP-1 receptor agonists are already being investigated for heart disease, kidney disease, liver disease, and addiction. This review adds asthma to the growing list of conditions where weight reduction via peptide therapy could have major clinical benefits. If trials confirm that semaglutide or tirzepatide improve asthma outcomes, it would represent yet another expansion of the GLP-1 revolution beyond metabolic disease.
Questions still open
- Will GLP-1 agonists improve asthma outcomes beyond what would be expected from weight loss alone, through their anti-inflammatory properties?
- Should asthma treatment guidelines be updated to formally recommend weight management as a first-line intervention for obese patients?
- How do adipokine-mediated inflammatory pathways interact with traditional Type-2 asthma biology in patients with obesity?
Common questions
Can GLP-1 weight loss drugs help with asthma?
Why does obesity make asthma worse?
Read the original research
Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum.
The European respiratory journal
Citation
Riemann, Sebastian; Matthys, Imke; Maes, Tania; Lapauw, Bruno; Brusselle, Guy. (2026). Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum.. The European respiratory journal. https://doi.org/10.1183/13993003.02687-2025